首页 | 官方网站   微博 | 高级检索  
     


Low‐dose acitretin in Papillon–Lefèvre syndrome: treatment and 1‐year follow‐up
Authors:Nilendu Sarma  Chiranjit Ghosh  Sudipta Kar  Badruddin Ahmed Bazmi
Affiliation:1. Department of Dermatology, NRS Medical College, Kolkata, India;2. Department of Pedodontics and Preventive Dentistry, Institute of Dental Sciences and Hospital, Bhuvaneshwar, India;3. Department of Pedodontics and Preventive Dentistry, Guru Nanak Institute of Dental Science and Research, Kolkata, West Bengal, India
Abstract:The Papillon–Lefèvre syndrome (PLS) is a rare, autosomal recessive disease that manifests with palmoplantar keratoderma and destructive periodontitis resulting in early onset periodontal breakdown in deciduous and permanent dentition. Management of this condition is difficult. Here we report one 11‐year‐old consanguineous Muslim boy suffering from PLS. After failing to get any benefit from methotrexate, three cycles of acitretin, each for 2 months, were given 1 month apart. In each cycle, acitretin (25 mg) was given every other day. At the end of the third cycle, treatment was stopped for 4 months to observe the extent of relapse. Thereafter, acitretin (25 mg) was given twice weekly for 4 months and then the patient was followed up for 1 year. Treatment with acitretin resulted in excellent improvement of periodontitis, increase in the alveolar bone height, and periodontal attachment. Improvement remained stable at the end of 1‐year follow‐up. There was excellent (>75%) improvement in keratoderma at the end of active therapy. Mild worsening of palmoplantar keratoderma was noticed whenever the drug was stopped. It improved when the drug was restarted. Other areas remained stable. At the end of 1‐year follow‐up, good improvement (50%) in palmoplantar keratoderma was achieved.
Keywords:acitretin  alveolar bone  palmoplantar keratoderma  Papillon–  Lefè  vre syndrome  periodontitis
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号